Biotech firm 'will not charge'NHS for breast cancer tests

Scottish biotechnology firm Rosgen has announced that it does not plan to charge the NHS for carrying out tests for mutations in two genes linked to breast cancer.

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here